Description

This combination delivers lopinavir—a potent HIV-1 protease inhibitor—with ritonavir, which inhibits CYP3A metabolism, boosting lopinavir levels. Both agents bind extensively to plasma proteins (~98–99%), offering stable plasma exposure. Historically used in multiple antiviral and viral replication studies, this formulation supports modeling HIV-1 protease suppression, antiviral drug synergy, and pharmacokinetic interactions. Supplied as 120 film?coated tablets sized for standard adult doses. For laboratory research only.

Lopinavir Ritonavir Product Specifications

Lopinavir Ritonavir Mechanism of Action & Research Applications

Lopinavir inhibits HIV-1 protease, essential for viral polyprotein processing, while ritonavir boosts its bioavailability by inhibiting CYP3A4-mediated metabolism. This dual functionality allows detailed modeling of protease suppression, pharmacokinetic boosting, viral replication assays, and resistance emergence studies. The combination is well-suited for laboratory research in HIV antiviral screening, drug interaction modeling, and combinatorial therapy evaluation.

Lopinavir Ritonavir Side Effects (For Reference Only in Research Models)

In experimental analogs and clinical data, common observations include gastrointestinal symptoms (nausea, vomiting, diarrhea), headache, fatigue, elevated lipids, liver function changes, rash, and potential CYP-mediated drug interactions. Prolonged or high-dose exposure may induce hepatic or cardiac tolerance responses. Data serve as reference for safety profile design in research dosing.

Disclaimer

Lopinavir?Ritonavir Tablets (AiDuan) are strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.